Meeder Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Meeder Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,120	Closed	-$5K	–	2687
2020 Q1	$5K	Buy	+1,120	New	+$7.26K	﹤0.01%	1836
2019 Q1	–	Sell	-790	Closed	-$8K	–	1948
2018 Q4	$8K	Buy	+790	New	+$10.2K	﹤0.01%	1317
2018 Q2	–	Sell	-90	Closed	-$1K	–	1745
2018 Q1	$1K	Sell	90 -254	-74%	-$3.96K	﹤0.01%	1517
2017 Q4	$5K	Buy	+344	New	+$4.6K	﹤0.01%	1338
2017 Q3	–	Sell	-237	Closed	-$2K	–	1821
2017 Q2	$2K	Hold	237	–	–	﹤0.01%	1462
2017 Q1	$2K	Sell	237 -681	-74%	-$6.21K	﹤0.01%	1446
2016 Q4	$10K	Buy	+918	New	+$11.1K	﹤0.01%	764

Meeder Asset Management's STML Position: Q2 2020 in Review

Meeder Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 1,120 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in STML in Q4 2016 and held it in 7 quarters. The position peaked at $10K in Q4 2016. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Meeder Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 1,120 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $5K.
Meeder Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
Meeder Asset Management's Stemline Therapeutics, Inc. position peaked at $10K in Q4 2016.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.